Atlas Venture Fund XI, L.P. - 12 Dec 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
10%+ Owner
Signature
Atlas Venture Fund XI, L.P., By: Atlas Venture Associates XI, L.P., its general partner, By: Atlas Venture Associates XI, LLC, its general partner, By: Ommer Chohan, Chief Financial Officer /s/ Ommer Chohan
Issuer symbol
DAWN
Transactions as of
12 Dec 2022
Transactions value $
$0
Form type
4
Filing time
14 Dec 2022, 15:54:24 UTC
Previous filing
19 Sep 2022
Next filing
16 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Other $0 -601K -9.09% $0.00 6.01M 12 Dec 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI") to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted by Atlas Venture Fund XI pursuant to Rule 10b5-1 on August 19, 2022.